AstraZeneca (AZN -0.3%) biologics R&D unit MedImmune and Incyte (INSY -6%) collaborate on a Phase 1/2 clinical trial to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor MEDI4736 in combination with Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.
MEDI4736 blocks the signals that help tumors avoid detection by the immune system while INCB24360 enhances immune cells' ability to fight the tumor.
The two firms collaborate on a non-exclusive basis. They expect the Phase 1 trial to establish a recommended dose regimen and Phase 2 to assess the safety and efficacy of the combination. Further development of the combo is contingent on the results of the trials.